434 related articles for article (PubMed ID: 15817912)
1. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.
Selvarajah D; Webster J; Ross R; Newell-Price J
Eur J Endocrinol; 2005 Apr; 152(4):569-74. PubMed ID: 15817912
[TBL] [Abstract][Full Text] [Related]
2. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
Cozzi R; Attanasio R; Lodrini S; Lasio G
Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
[TBL] [Abstract][Full Text] [Related]
3. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
[TBL] [Abstract][Full Text] [Related]
4. Cabergoline treatment of acromegaly: a preliminary dose finding study.
Jackson SN; Fowler J; Howlett TA
Clin Endocrinol (Oxf); 1997 Jun; 46(6):745-9. PubMed ID: 9274706
[TBL] [Abstract][Full Text] [Related]
5. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists.
Howlett TA; Willis D; Walker G; Wass JA; Trainer PJ;
Clin Endocrinol (Oxf); 2013 Nov; 79(5):689-99. PubMed ID: 23574573
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
7. Clinical use of cabergoline as primary and adjunctive treatment for acromegaly.
Moyes VJ; Metcalfe KA; Drake WM
Eur J Endocrinol; 2008 Nov; 159(5):541-5. PubMed ID: 18708434
[TBL] [Abstract][Full Text] [Related]
8. COMPARISON OF CABERGOLINE VERSUS RALOXIFENE ADD-ON THERAPY TO LONG-ACTING SOMATOSTATIN ANALOGUE IN PATIENTS WITH INADEQUATELY CONTROLLED ACROMEGALY: A RANDOMIZED OPEN LABEL CLINICAL TRIAL.
Imani M; Khamseh ME; Asadi P; Ghorbani M; Akbari H; Alaei-Shahmiri F; Honardoost M; Kaynama MR; Malek M
Endocr Pract; 2018 Jun; 24(6):542-547. PubMed ID: 29949429
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of medical treatment in patients with acromegaly in clinical practice.
Lee SY; Kim JH; Lee JH; Kim YH; Cha HJ; Kim SW; Paek SH; Shin CS
Endocr J; 2018 Jan; 65(1):33-41. PubMed ID: 28931779
[TBL] [Abstract][Full Text] [Related]
10. Remission of acromegaly following long-term therapy with cabergoline: report of two cases.
Verhelst JA; Abrams PJ; Abs R
Pituitary; 2008; 11(1):103-7. PubMed ID: 17530416
[TBL] [Abstract][Full Text] [Related]
11. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly.
Mattar P; Alves Martins MR; Abucham J
Neuroendocrinology; 2010; 92(2):120-7. PubMed ID: 20802256
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?
Cozzi R; Attanasio R; Grottoli S; Pagani G; Loli P; Gasco V; Pedroncelli AM; Montini M; Ghigo E
J Endocrinol Invest; 2004 Dec; 27(11):1040-7. PubMed ID: 15754736
[TBL] [Abstract][Full Text] [Related]
14. Cabergoline in the treatment of acromegaly: a study in 64 patients.
Abs R; Verhelst J; Maiter D; Van Acker K; Nobels F; Coolens JL; Mahler C; Beckers A
J Clin Endocrinol Metab; 1998 Feb; 83(2):374-8. PubMed ID: 9467544
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcome results from the Bulgarian Acromegaly Database: adjuvant dopamine agonist therapy is efficient in less than one fifth of non-irradiated patients.
Vandeva S; Elenkova A; Natchev E; Kirilov G; Tcharaktchiev D; Yaneva M; Kalinov K; Marinov M; Hristozov K; Kamenov Z; Orbetzova M; Gerenova J; Tsinlikov I; Zacharieva S
Exp Clin Endocrinol Diabetes; 2015 Jan; 123(1):66-71. PubMed ID: 25611123
[TBL] [Abstract][Full Text] [Related]
16. Medical therapy for acromegaly.
Newman CB
Endocrinol Metab Clin North Am; 1999 Mar; 28(1):171-90. PubMed ID: 10207690
[TBL] [Abstract][Full Text] [Related]
17. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.
Jallad RS; Bronstein MD
Neuroendocrinology; 2009; 90(1):82-92. PubMed ID: 19439914
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.
Marzullo P; Ferone D; Di Somma C; Pivonello R; Filippella M; Lombardi G; Colao A
Pituitary; 1999; 1(2):115-20. PubMed ID: 11081189
[TBL] [Abstract][Full Text] [Related]
19. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
Arihara Z; Sakurai K; Yamashita R; Niitsuma S; Ueno T; Yamamura N; Yamada S; Inoshita N; Takahashi K
Tohoku J Exp Med; 2014 Oct; 234(2):129-35. PubMed ID: 25253414
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
Suda K; Inoshita N; Iguchi G; Fukuoka H; Takahashi M; Nishizawa H; Yamamoto M; Yamada S; Takahashi Y
Endocr J; 2013; 60(4):507-15. PubMed ID: 23291436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]